{"id":35312,"date":"2025-06-17T00:02:19","date_gmt":"2025-06-16T16:02:19","guid":{"rendered":"https:\/\/flcube.com\/?p=35312"},"modified":"2025-06-17T00:02:20","modified_gmt":"2025-06-16T16:02:20","slug":"fosun-pharmas-serplulimab-approved-in-singapore-and-malaysia-for-es-sclc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35312","title":{"rendered":"Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment"},"content":{"rendered":"\n

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196<\/a>, SHA: 600196<\/a>) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696<\/a>) has secured approvals from Singapore’s Health Sciences Authority (HSA) and Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) for its self – developed anti – PD – 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive – stage small cell lung cancer (ES – SCLC). The drug will be available under the brand name Zerpidio in these markets.<\/p>\n\n\n\n

Global Presence and Patient Impact<\/strong><\/p>\n\n\n\n

Serplulimab has already gained approval in over 30 countries and regions around the world, benefiting more than 110,000 patients. Its expanded reach underscores Fosun Pharma’s commitment to addressing unmet medical needs in oncology.<\/p>\n\n\n\n

Strategic Licensing and Commercialization Partnerships<\/strong><\/p>\n\n\n\n

Henlius entered into an exclusive licensing agreement with KGbio in 2019, granting the latter development and commercialization rights for the drug in ASEAN countries. In August 2023, the partnership was expanded to grant KGbio exclusive rights for two indications, including ES – SCLC, in 12 Middle East and North Africa (MENA) countries. KGbio will spearhead commercialization efforts in Southeast Asian markets going forward, marking a significant step in the drug’s global expansion.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai…<\/p>\n","protected":false},"author":1,"featured_media":35313,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[159,270,893,862,18,15,892],"class_list":["post-35312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-fosun-pharmaceutical","tag-henlius-biotech","tag-hkg-2196","tag-hkg-2696","tag-pd-1-l1","tag-product-approvals","tag-sha-600196"],"yoast_head":"\nFosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has secured approvals from Singapore's Health Sciences Authority (HSA) and Malaysia's National Pharmaceutical Regulatory Agency (NPRA) for its self - developed anti - PD - 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive - stage small cell lung cancer (ES - SCLC). The drug will be available under the brand name Zerpidio in these markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35312\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has secured approvals from Singapore's Health Sciences Authority (HSA) and Malaysia's National Pharmaceutical Regulatory Agency (NPRA) for its self - developed anti - PD - 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive - stage small cell lung cancer (ES - SCLC). The drug will be available under the brand name Zerpidio in these markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35312\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T16:02:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T16:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1604-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment\",\"datePublished\":\"2025-06-16T16:02:19+00:00\",\"dateModified\":\"2025-06-16T16:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312\"},\"wordCount\":208,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1604-1.webp\",\"keywords\":[\"Fosun Pharmaceutical\",\"Henlius Biotech\",\"HKG: 2196\",\"HKG: 2696\",\"PD-1\\\/L1\",\"Product approvals\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35312#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35312\",\"name\":\"Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1604-1.webp\",\"datePublished\":\"2025-06-16T16:02:19+00:00\",\"dateModified\":\"2025-06-16T16:02:20+00:00\",\"description\":\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has secured approvals from Singapore's Health Sciences Authority (HSA) and Malaysia's National Pharmaceutical Regulatory Agency (NPRA) for its self - developed anti - PD - 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive - stage small cell lung cancer (ES - SCLC). The drug will be available under the brand name Zerpidio in these markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35312\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1604-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1604-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35312#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment - Insight, China's Pharmaceutical Industry","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has secured approvals from Singapore's Health Sciences Authority (HSA) and Malaysia's National Pharmaceutical Regulatory Agency (NPRA) for its self - developed anti - PD - 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive - stage small cell lung cancer (ES - SCLC). The drug will be available under the brand name Zerpidio in these markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35312","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment","og_description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has secured approvals from Singapore's Health Sciences Authority (HSA) and Malaysia's National Pharmaceutical Regulatory Agency (NPRA) for its self - developed anti - PD - 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive - stage small cell lung cancer (ES - SCLC). The drug will be available under the brand name Zerpidio in these markets.","og_url":"https:\/\/flcube.com\/?p=35312","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-16T16:02:19+00:00","article_modified_time":"2025-06-16T16:02:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1604-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35312#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35312"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment","datePublished":"2025-06-16T16:02:19+00:00","dateModified":"2025-06-16T16:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35312"},"wordCount":208,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1604-1.webp","keywords":["Fosun Pharmaceutical","Henlius Biotech","HKG: 2196","HKG: 2696","PD-1\/L1","Product approvals","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35312#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35312","url":"https:\/\/flcube.com\/?p=35312","name":"Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35312#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1604-1.webp","datePublished":"2025-06-16T16:02:19+00:00","dateModified":"2025-06-16T16:02:20+00:00","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has secured approvals from Singapore's Health Sciences Authority (HSA) and Malaysia's National Pharmaceutical Regulatory Agency (NPRA) for its self - developed anti - PD - 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive - stage small cell lung cancer (ES - SCLC). The drug will be available under the brand name Zerpidio in these markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35312#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35312"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35312#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1604-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1604-1.webp","width":1080,"height":608,"caption":"Fosun Pharma's Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35312#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1604-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35312"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35312\/revisions"}],"predecessor-version":[{"id":35314,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35312\/revisions\/35314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35313"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}